Zimmer Partners’s GSK GSK Stock Holding History

Zimmer Partners’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-400,000	Closed	-$17.3M	–	142
2025 Q3	$17.3M	Buy	+400,000	New	+$15.6M	0.37%	58

Other funds holding GSK

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Zimmer Partners's GSK Position: Q4 2023 in Review

Zimmer Partners sold out of GSK (GSK) in Q4 2023, closing a stake of 204,081 shares — an estimated $7.4M sold.

Zimmer Partners first reported a position in GSK in Q3 2023 and held it in 1 quarter. The position peaked at $7.4M in Q3 2023. 895 funds tracked by Wall St. Rank hold GSK as of Q4 2023.

Zimmer Partners reported no remaining GSK position as of Q4 2023 after selling out during the quarter.
Zimmer Partners sold 204,081 GSK shares in Q4 2023, an estimated $7.4M.
Zimmer Partners first reported a position in GSK in Q3 2023 and held it in 1 quarter.
Zimmer Partners's GSK position peaked at $7.4M in Q3 2023.
895 funds tracked by Wall St. Rank held GSK as of Q4 2023.

Based on Zimmer Partners's 13F filing for Q4 2023, filed 14 Feb 2024.